Business
Novavax Nears Covid-19 Vaccine Game Changer—After Years of Failure – The Wall Street Journal
If authorized, its shot could be one of the more powerful weapons against the pandemic
In January of last year, employees of Novavax Inc. met at a local Maryland bar to discuss how they might salvage their careers. For decades, the small biotech had tried to develop an approved vaccine, with no success. The company had enough cash to survive only another six months or so and its shares traded under $4, with a market value of $127 million.
Today, Novavax is advancing toward authorization of a Covid-19 vaccine. Scientists believe that, if cleared, it could be one of the more powerful…
